Carl Harald Jansonm, lead investment manager on the International Biotechnology investment trust, looks at how the sector has fared following the most recent sell-off
The US biotechnology sector’s stupendous bull run went into sharp reverse in August when the NASDAQ biotechnology index plunged by more than 20% from its peak value in July, before recovering. The...
Four potential outcomes
Industry members abseil down Broadgate Tower
Changes made on 14 September
Hired as portfolio manager in global equity income team
'Three cycles are colliding'